Splenic Infarct, Atrial Fibrillation

More documents

Recommendations

Info

ROCKET : Rivaroxaban vs. Warfarin: Cumulative Rates of the Primary End Point during Treatment and after Discontinuation in the Intention-to-Treat Population. Patel MR et al. N Engl J Med 2011;365:883-891
ROCKET: Rivaroxaban vs. Warfarin: Rates of Bleeding Events. Patel MR et al. N Engl J Med 2011;365:883-891
Page 1 and 2: Morning report Resident: Bijan Ghas
Page 3 and 4: MKSAP A 43-year-old man is evaluate
Page 5 and 6: MKSAP Which of the following is the
Page 7 and 8: MKSAP Because a bicuspid valve is s
Page 9 and 10: HPI Pain History: Location: Diffus
Page 11 and 12: Physical Exam Vitals: T 38.3 HR 60
Page 13 and 14: CXR
Page 15 and 16: CT abdomen New splenic broad wedge
Page 17 and 18: Differential Diagnosis of Splenic I
Page 19 and 20: Modified Duke Criteria for the Diag
Page 21 and 22: TEE Read: - No evidence of vegetati
Page 23 and 24: This is what you see . . . . Though
Page 25 and 26: OUR PATIENTS A-FIB WAS A BIT HARDER
Page 27 and 28: OUR PATIENTS RECENT EKGS
Page 29 and 30: OUR PATIENTS RECENT EKGS
Page 31 and 32: Our patients recent EKgs
Page 33 and 34: Patient transitioned from heparin t
Page 35 and 36: Can it still go somewhere else? Leu
Page 37 and 38: Warfarin: Results in biologically i
Page 39: RE-LY: Dabigtran vs Warfarin for A-
Page 43 and 44: ARISTOTLE: Apixaban vs. Warfarin fo
Page 45 and 46: RE-COVER: Dabigatran vs. Warfarin f
Page 47: SUMMARY DIFFERENTIAL AND WORKUP FOR

Splenic Infarct, Atrial Fibrillation

Create successful ePaper yourself

Delete template?

Save as template?